Skip to main content

Respiratory Insufficiency

Respiratory
2
Pipeline Programs
9
Companies
11
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
1
0
Early DiscoveryClinical DevelopmentMarket

Respiratory is a $39.4B mature market dominated by established inhalers and combination therapies with significant patent cliff risk.

$39.4B marketMature→ Stable30 products15 companies

Key Trends

  • Consolidation around GSK's triple-therapy franchises (Trelegy, Breo, Anoro)
  • Major patent expirations 2026-2031 creating $7.8B revenue cliff
  • High clinical trial activity (4,862 trials) suggesting pipeline innovation despite market maturity

Career Verdict

Respiratory offers stable commercial careers but limited growth upside; best for professionals seeking established markets with strong commercial infrastructure rather than innovation-driven advancement.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISGrowing
$18.3B
Bristol Myers Squibb·Launch15.0yr
#3TRELEGY ELLIPTADeclining
$4.5B
GSK·Peak4.9yr
#4CREONDeclining
$1.5B
AbbVie·Approaching LOE
#5BREO ELLIPTADeclining
$1.4B
GSK·Peak4.9yr

Drug Class Breakdown

FXa Inhibitors
$18.3B(46%)

dominant market driver

Unknown/Undisclosed Mechanism
$9.7B(25%)

fragmented portfolio

GLP-1 Receptor Agonists
$7.4B(19%)

rapidly expanding

Pancreatic Enzymes
$1.5B(4%)

legacy product

Corticosteroid/LABA Combinations
$796M(2%)

patent cliff approaching

Long-Acting Muscarinic Antagonists
$456M(1%)

mature maintenance therapy

Career Outlook

Stable

Respiratory is a stable, mature market suitable for commercial and medical affairs professionals seeking established career paths, but offers limited growth or innovation-focused opportunities. The impending patent cliff ($7.8B+ revenue at risk 2026-2031) will drive near-term restructuring and consolidation, potentially reducing headcount in 2027-2028. Professionals should expect strong compensation in Medical Affairs and field roles but limited advancement into strategic or R&D positions.

Breaking In

New graduates should prioritize commercial, field-based, or Medical Affairs roles over R&D; respiratory offers structured training and stable compensation but limited innovation exposure, so pair this experience with cross-therapeutic skill-building for long-term mobility.

For Experienced Professionals

Experienced professionals should evaluate whether to maximize earnings in this mature, stable market or transition to higher-growth areas (oncology, cell therapy); respiratory consolidation 2027-2030 will reduce senior-level opportunities, so consider strategic moves before patent cliff impacts headcount.

In-Demand Skills

Commercial execution and territory managementMedical Affairs/Key Opinion Leader engagementRegulatory affairs and lifecycle managementInhalation device expertise and product trainingManaged care and payer negotiations

Best For

Brand ManagerMedical Science LiaisonRegional Sales ManagerField Medical RepresentativePayer Relations ManagerRegulatory Specialist

Hiring Landscape

$84K-$314K

The respiratory sector shows modest hiring momentum (510 jobs across tracked positions) concentrated in commercial and engineering roles, with AstraZeneca and GSK leading. Medical Affairs positions command premium salaries ($314K avg) but represent only 3% of openings, reflecting the mature market's focus on sales execution over innovation. Hiring velocity is moderate and reflects market consolidation rather than expansion, suggesting limited career progression opportunities for early-to-mid career professionals.

510
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

43Stable
70Growing
45Stable
15Stable

By Department

Commercial(23%)
$122K
Engineering(11%)
$111K
Medical Affairs(3%)
$314K
IT(4%)
$84K
Manufacturing(3%)

Respiratory hiring favors commercial and field-based roles over R&D; Medical Affairs roles offer premium compensation but are scarce, making this area competitive for specialized talent.

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
1 program
1
BNP-guided weaningPhase 31 trial
Active Trials
NCT00473148Completed265Est. Mar 2010
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
Nalbuphine hydrochloride injectionPhase 2/3
Eppendorf
EppendorfGermany - Hamburg
3 programs
Single Use Bronchoscopy for PDTN/A1 trial
VivaSight intubationN/A1 trial
conventional bronchoscopyN/A1 trial
Active Trials
NCT03952247Completed46Est. Nov 2019
NCT02837055Completed54Est. Jan 2018
NCT02861001Completed56Est. Jan 2017
ResMed
ResMedSAN DIEGO, CA
2 programs
AutoVPAP with addition of AutoEPAPN/A1 trial
JunoN/A1 trial
Active Trials
NCT01403584Completed21Est. Feb 2015
NCT02317042Terminated25Est. Nov 2015
Bactiguard
BactiguardSweden - Tullinge
1 program
Endotracheal tubeN/A1 trial
Active Trials
NCT02284438Completed102Est. Feb 2020
Medtronic
MedtronicNJ - Phillipsburg
1 program
Novel Non-Invasive Monitoring Parameter in a Hospital SettingN/A1 trial
Active Trials
NCT01306201Completed63Est. Mar 2012
Nonin
NoninMN - Plymouth
1 program
Respiratory Rate Accuracy Verification Clinical: Pulmonary Rehabilitation PatientsN/A1 trial
Active Trials
NCT03592914Completed60Est. Jan 2019
Philips
PhilipsNetherlands - Amsterdam
1 program
TrilogyN/A1 trial
Active Trials
NCT00810498Completed11Est. Feb 2009
Humanwell Pharmaceutical
1 program
Nalbuphine hydrochloride injectionPHASE_2_31 trial
Active Trials
NCT06785571Recruiting204Est. Oct 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbottBNP-guided weaning
Humanwell PharmaceuticalNalbuphine hydrochloride injection
EppendorfSingle Use Bronchoscopy for PDT
NoninRespiratory Rate Accuracy Verification Clinical: Pulmonary Rehabilitation Patients
EppendorfVivaSight intubation
Eppendorfconventional bronchoscopy
ResMedJuno
BactiguardEndotracheal tube
ResMedAutoVPAP with addition of AutoEPAP
MedtronicNovel Non-Invasive Monitoring Parameter in a Hospital Setting
PhilipsTrilogy

Clinical Trials (11)

Total enrollment: 907 patients across 11 trials

NCT00473148AbbottBNP-guided weaning

B-type Natriuretic Peptide for the Management of Weaning

Start: Jun 2007Est. completion: Mar 2010265 patients
Phase 3Completed
NCT06785571Humanwell PharmaceuticalNalbuphine hydrochloride injection

The Evaluation of the Effectiveness and Safety of Nalbuphine Hydrochloride Injection for Analgesia in ICU Patients: A Multicenter, Randomized, Single-blinded, Parallel, Two-step Trial

Start: Aug 2023Est. completion: Oct 2025204 patients
Phase 2/3Recruiting
NCT03952247EppendorfSingle Use Bronchoscopy for PDT

"TRAcheostomy With Single Use Bronchoscopes vs. Conventional Bronchoscopes"

Start: May 2019Est. completion: Nov 201946 patients
N/ACompleted
NCT03592914NoninRespiratory Rate Accuracy Verification Clinical: Pulmonary Rehabilitation Patients

Respiratory Rate Accuracy Verification Clinical: Pulmonary Rehabilitation Patients

Start: Jul 2018Est. completion: Jan 201960 patients
N/ACompleted
NCT02837055EppendorfVivaSight intubation

Conventional Intubation Versus VivaSight™-SL

Start: Apr 2016Est. completion: Jan 201854 patients
N/ACompleted
NCT02861001Eppendorfconventional bronchoscopy

VivaSight-SL™ Versus Bronchoscopy for Percutaneous Tracheotomy

Start: Apr 2016Est. completion: Jan 201756 patients
N/ACompleted

Juno Perth Clinical Trial

Start: May 2015Est. completion: Nov 201525 patients
N/ATerminated
NCT02284438BactiguardEndotracheal tube

Biofilm Formation on Different Endotracheal Tube Materials

Start: Apr 2014Est. completion: Feb 2020102 patients
N/ACompleted
NCT01403584ResMedAutoVPAP with addition of AutoEPAP

Adjustment of Mask Pressure, for Bilevel Positive Airways Pressure Therapy, by Automated Algorithm

Start: Jul 2011Est. completion: Feb 201521 patients
N/ACompleted
NCT01306201MedtronicNovel Non-Invasive Monitoring Parameter in a Hospital Setting

Novel Non-Invasive Monitoring Parameter in a Hospital Setting

Start: Feb 2011Est. completion: Mar 201263 patients
N/ACompleted

Trilogy Comparison Study - Adults

Start: Mar 2008Est. completion: Feb 200911 patients
N/ACompleted

Related Jobs in Respiratory

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 907 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.